It is challenging to characterize the drug-related problems(DRPs)of patients treated by Integrated Traditional Chinese and Western Medicine(ITCWM),both locally and globally.In the present study,we aimed to assess DRPs...It is challenging to characterize the drug-related problems(DRPs)of patients treated by Integrated Traditional Chinese and Western Medicine(ITCWM),both locally and globally.In the present study,we aimed to assess DRPs and factors associated with their occurrence among inpatients of the ITCWM department in China.We retrospectively examined medication use in the ITCWM department,documented in Intelligent Management System Software for Critical Rational Administration of Drug.Various types of DRPs classification were performed based on the Pharmaceutical Care Network Europe(PCNE)classification tool V9.0,and associations of patient’s characteristics were analyzed.A total of 1606 DRPs were identified in 687 inpatients in this study.Problems and causes of DRPs,intervention,acceptance,and outcome of that were classified.PPI(21.7%),endogenous supplements(15.4%),and traditional Chinese medicine(8.7%)contributed to the significant proportion of drug categories associated with DRPs.Approximately half of the patients(47.6%)had at least one DRP.The top four categories of causes were“drug administered via the wrong route”(18.4%),“inappropriate combination”(16.7%),“too long duration of the treatment”(13.0%),and“inappropriate drug form”(12.1%).Total 63.6%of intervention was accepted and fully implemented.“EPP”and“hospital stay days≥10 d”characteristics were most likely to be significantly associated with DRPs.As a necessary review item,DRP was highly performed among inpatients of the ITCWM department.The work provided a benchmark for this population through the PCNE strategy.展开更多
目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床...目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床应用指南》(2021年版)梳理所有活血化瘀类中药注射剂,根据其药品说明书信息、指南信息和临床使用情况,设立评价指标,运用德尔菲法建立评价标准。收集2022年1月1日至6月30日某院心内科活血化瘀类中药注射剂使用数据,采用评价标准结合优劣解距离法(technique for order preference by similarity to an ideal solution,TOPSIS)进行评价。结果 共纳入21种活血化瘀类中药注射剂适应证,分别从适应证、溶媒、用法用量、辅料和溶剂、配伍使用、特殊人群等方面建立一级、二级评价指标。根据评价结果分析120例心内科使用活血化瘀类中药注射剂患者中,相对接近度(Ci)≥60%的有107例(89.17%),表明某院心内科使用活血化瘀类中药注射剂应用情况基本合理。结论 评价标准的建立有利于提高活血化瘀类中药注射剂使用的合理性,可促进活血化瘀类中药注射剂临床的安全使用。展开更多
基金National Major New Drug Creation Project of China(Grant No.2020ZX09201-009)。
文摘It is challenging to characterize the drug-related problems(DRPs)of patients treated by Integrated Traditional Chinese and Western Medicine(ITCWM),both locally and globally.In the present study,we aimed to assess DRPs and factors associated with their occurrence among inpatients of the ITCWM department in China.We retrospectively examined medication use in the ITCWM department,documented in Intelligent Management System Software for Critical Rational Administration of Drug.Various types of DRPs classification were performed based on the Pharmaceutical Care Network Europe(PCNE)classification tool V9.0,and associations of patient’s characteristics were analyzed.A total of 1606 DRPs were identified in 687 inpatients in this study.Problems and causes of DRPs,intervention,acceptance,and outcome of that were classified.PPI(21.7%),endogenous supplements(15.4%),and traditional Chinese medicine(8.7%)contributed to the significant proportion of drug categories associated with DRPs.Approximately half of the patients(47.6%)had at least one DRP.The top four categories of causes were“drug administered via the wrong route”(18.4%),“inappropriate combination”(16.7%),“too long duration of the treatment”(13.0%),and“inappropriate drug form”(12.1%).Total 63.6%of intervention was accepted and fully implemented.“EPP”and“hospital stay days≥10 d”characteristics were most likely to be significantly associated with DRPs.As a necessary review item,DRP was highly performed among inpatients of the ITCWM department.The work provided a benchmark for this population through the PCNE strategy.
文摘目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床应用指南》(2021年版)梳理所有活血化瘀类中药注射剂,根据其药品说明书信息、指南信息和临床使用情况,设立评价指标,运用德尔菲法建立评价标准。收集2022年1月1日至6月30日某院心内科活血化瘀类中药注射剂使用数据,采用评价标准结合优劣解距离法(technique for order preference by similarity to an ideal solution,TOPSIS)进行评价。结果 共纳入21种活血化瘀类中药注射剂适应证,分别从适应证、溶媒、用法用量、辅料和溶剂、配伍使用、特殊人群等方面建立一级、二级评价指标。根据评价结果分析120例心内科使用活血化瘀类中药注射剂患者中,相对接近度(Ci)≥60%的有107例(89.17%),表明某院心内科使用活血化瘀类中药注射剂应用情况基本合理。结论 评价标准的建立有利于提高活血化瘀类中药注射剂使用的合理性,可促进活血化瘀类中药注射剂临床的安全使用。
